Statement of deviation for the quarter ended on March 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bharat Parenterals filed its quarterly statement on the use of funds raised through a preferential issue of equity shares. The company had raised Rs. 95.60 crore on May 28, 2024, earmarked across three purposes: Rs. 7.17 crore for business expansion capital adequacy, Rs. 76.48 crore for investment in a subsidiary company, and Rs. 11.95 crore for general corporate purposes. As of March 31, 2025, Rs. 64.80 crore has been deployed into the subsidiary, Rs. 11.95 crore fully used for general corporate purposes, while no amount has yet been spent on the expansion allocation. Total utilisation stands at Rs. 76.75 crore out of Rs. 95.60 crore raised.
The filing confirms there is no deviation from the originally stated objects of the issue, which is a positive compliance signal. Shareholders can note that nearly 80% of the raised capital has already been deployed, mainly into a subsidiary, though Rs. 7.17 crore earmarked for expansion remains unutilised and could warrant tracking in future quarters.